First-in-class Oral Small Molecule Inhibitor of the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2018 May 5

PMID 29725030

Citations 26

Authors

M Hojjat-Farsangi

A H Daneshmanesh

A S Khan

J Shetye

F Mozaffari

P Kharaziha

L-S Rathje

P Kokhaei

L Hansson

J Vagberg

S Bystrom

E Olsson

C Lofberg

C Norstrom

J Schultz

M Norin

T Olin

A Osterborg

H Mellstedt

A Moshfegh

Affiliations

Soon will be listed here.

Citing Articles

The Multi-Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre-Clinical Efficacy in Endometrial Cancer.

Liu D, Glubb D, OMara T, Ford C Cancer Med. 2024; 14(1):e70531.

PMID: 39739675 PMC: 11683556. DOI: 10.1002/cam4.70531.

Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.

Sobczynska-Konefal A, Jasek M, Karabon L, Jaskula E Biomark Res. 2024; 12(1):162.

PMID: 39732734 PMC: 11682641. DOI: 10.1186/s40364-024-00710-w.

Overview on Immunopathology of Chronic Lymphocytic Leukemia and Tumor-Associated Antigens with Therapeutic Applications.

Shabani M, Rostamzadeh D, Mansouri M, Jeddi-Tehrani M Avicenna J Med Biotechnol. 2024; 16(4):201-222.

PMID: 39606680 PMC: 11589431. DOI: 10.18502/ajmb.v16i4.16737.

Therapeutic advances in the targeting of ROR1 in hematological cancers.

Tigu A, Munteanu R, Moldovan C, Rares D, Kegyes D, Tomai R Cell Death Discov. 2024; 10(1):471.

PMID: 39551787 PMC: 11570672. DOI: 10.1038/s41420-024-02239-1.

Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies.

Li L, Huang W, Ren X, Wang Z, Ding K, Zhao L Sci China Life Sci. 2024; 67(12):2603-2616.

PMID: 39145866 DOI: 10.1007/s11427-024-2685-9.

References

Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C . NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012; 21(3):348-61. DOI: 10.1016/j.ccr.2012.02.008. View

Bengoa-Vergniory N, Gorrono-Etxebarria I, Lopez-Sanchez I, Marra M, Di Chiaro P, Kypta R . Identification of Noncanonical Wnt Receptors Required for Wnt-3a-Induced Early Differentiation of Human Neural Stem Cells. Mol Neurobiol. 2016; 54(8):6213-6224. DOI: 10.1007/s12035-016-0151-5. View

Boggon T, Eck M . Structure and regulation of Src family kinases. Oncogene. 2004; 23(48):7918-27. DOI: 10.1038/sj.onc.1208081. View

Choudhury A, Derkow K, Daneshmanesh A, Mikaelsson E, Kiaii S, Kokhaei P . Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol. 2010; 151(4):327-35. DOI: 10.1111/j.1365-2141.2010.08362.x. View

Crassini K, Shen Y, Mulligan S, Best O . Modeling the chronic lymphocytic leukemia microenvironment in vitro. Leuk Lymphoma. 2016; 58(2):266-279. DOI: 10.1080/10428194.2016.1204654. View

Yu J, Chen L, Cui B, Wu C, Choi M, Chen Y . Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2016; 31(6):1333-1339. PMC: 5462858. DOI: 10.1038/leu.2016.368. View

Hojjat-Farsangi M, Moshfegh A, Daneshmanesh A, Khan A, Mikaelsson E, Osterborg A . The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 2014; 29:21-31. DOI: 10.1016/j.semcancer.2014.07.005. View

Desai A, El-Bakkar H, Abdul-Hay M . Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future. Clin Lymphoma Myeloma Leuk. 2014; 15(6):314-22. DOI: 10.1016/j.clml.2014.09.007. View

Zhang S, Chen L, Cui B, Chuang H, Yu J, Wang-Rodriguez J . ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012; 7(3):e31127. PMC: 3293865. DOI: 10.1371/journal.pone.0031127. View

10.

Daneshmanesh A, Hojjat-Farsangi M, Khan A, Jeddi-Tehrani M, Akhondi M, Bayat A . Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia. 2012; 26(6):1348-55. DOI: 10.1038/leu.2011.362. View

11.

Hojjat-Farsangi M, Khan A, Daneshmanesh A, Moshfegh A, Sandin A, Mansouri L . The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS One. 2013; 8(10):e78339. PMC: 3813472. DOI: 10.1371/journal.pone.0078339. View

12.

Tseng H, Kao H, Ho M, Chen Y, Lin T, Lyu P . Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase ROR1. Anticancer Res. 2011; 31(12):4239-49. View